Institute of hematology and blood transfusion (prague) to present on successful use of applied dna's linea dnatm for the non-viral manufacture of car t-cell therapy for refractory aml

Stony brook, ny / accesswire / may 13, 2024 / applied dna sciences, inc. (nasdaq:apdn) (applied dna), a leader in pcr-based dna technologies, and the institute of hematology and blood transfusion (Úhkt/ihbt) today announced that an abstract relating to the development of a fully enzymatic, non-viral manufacturing workflow to enable the rapid and cost-effective production of clinical-grade (gmp) car t-cell therapies has been accepted for presentation at the prestigious european hematology association 2024 hybrid congress to be held in madrid, spain from june 13 - 16, 2024. accepted abstracts will be available on the congress' website starting on may 14, 2024.
APDN Ratings Summary
APDN Quant Ranking